Pfizer Inc. $PFE Shares Bought by Ritholtz Wealth Management

Ritholtz Wealth Management increased its stake in Pfizer Inc. (NYSE:PFE) by 17.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 209,124 shares of the biopharmaceutical company’s stock after purchasing an additional 30,643 shares during the quarter. Ritholtz Wealth Management’s holdings in Pfizer were worth $5,872,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vermillion Wealth Management Inc. raised its position in shares of Pfizer by 19.4% during the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 382 shares in the last quarter. Triad Wealth Partners LLC lifted its stake in shares of Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares during the period. Eagle Capital Management LLC boosted its holdings in shares of Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after acquiring an additional 390 shares in the last quarter. ETF Store Inc. increased its stake in shares of Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after acquiring an additional 396 shares during the period. Finally, Mattern Wealth Management LLC increased its stake in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 400 shares during the period. Institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won FDA approval for an expanded IBRANCE regimen in metastatic breast cancer, a meaningful commercial and pipeline win for its oncology franchise.
• Positive Sentiment: The company advanced a pediatric pneumococcal “catch-up” vaccine into Phase 3, adding another potential growth catalyst to the pipeline.
• Positive Sentiment: Pfizer declared a $0.43 third-quarter dividend, extending its long streak of quarterly payouts and supporting the stock’s income profile.
• Neutral Sentiment: Pfizer reaffirmed its FY 2026 outlook despite leadership change chatter, which may help reassure investors but does not materially change the near-term growth story.
• Negative Sentiment: Sigvotatug vedotin missed its primary survival goal in Phase 3 lung cancer testing, renewing concerns about Pfizer’s oncology pipeline momentum and contributing to the stock’s weakness. Article Title

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on PFE shares. Bank of America cut their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Guggenheim upped their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research note on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.82.

Pfizer Stock Down 2.7%

PFE stock opened at $24.05 on Thursday. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The firm has a market cap of $137.07 billion, a PE ratio of 18.36 and a beta of 0.34. The firm has a 50 day simple moving average of $26.07 and a 200 day simple moving average of $26.31. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.